6C41

ICD-11 MMS 2026-01

Disorders due to use of cannabis

Description

Disorders due to use of cannabis are characterised by the pattern and consequences of cannabis use. Cannabis is the collective term for a range of psychoactive preparations of the cannabis plant, Cannabis sativa, and related species and hybrids. Cannabis contains cannabinoids, a class of diverse chemical compounds that act on endogenous cannabinoid receptors that modulate neurotransmitter release in the brain. The principal psychoactive cannabinoid is δ-9-tetrahydrocannabinol (THC). Cannabis is typically smoked in the form of the flowering heads or leaves of the Cannabis plant; tobacco is often mixed with cannabis when smoked. There are also cannabis oils that are prepared from these same sources. These preparations vary considerably in their THC potency. Cannabis has predominantly central nervous system depressant effects and produces a characteristic euphoria that may be part of the presenting features of Cannabis Intoxication, which may also include impairment in cognitive and psychomotor functioning. Cannabis has dependence-producing properties resulting in Cannabis Dependence in some people and Cannabis Withdrawal when use is reduced or discontinued. Cannabis is associated with a range of Cannabis-Induced Mental Disorders.

Excludes

  • 6C42 – Disorders due to use of synthetic cannabinoids
  • QE11.1 – Hazardous use of cannabis

Exclusions from above levels

  • QE62 – Uncomplicated bereavement
  • QE84 – Acute stress reaction

Child codes

  • 6C41.0 – Episode of harmful use of cannabis
  • 6C41.1 – Harmful pattern of use of cannabis
  • 6C41.2 – Cannabis dependence
  • 6C41.3 – Cannabis intoxication
  • 6C41.4 – Cannabis withdrawal
  • 6C41.5 – Cannabis-induced delirium
  • 6C41.6 – Cannabis-induced psychotic disorder
  • 6C41.7 – Certain specified cannabis-induced mental or behavioural disorders
  • 6C41.Y – Other specified disorders due to use of cannabis
  • 6C41.Z – Disorders due to use of cannabis, unspecified

Sibling codes

  • 6C40 – Disorders due to use of alcohol
  • 6C42 – Disorders due to use of synthetic cannabinoids
  • 6C43 – Disorders due to use of opioids
  • 6C44 – Disorders due to use of sedatives, hypnotics or anxiolytics
  • 6C45 – Disorders due to use of cocaine
  • 6C46 – Disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone
  • 6C47 – Disorders due to use of synthetic cathinones
  • 6C48 – Disorders due to use of caffeine
  • 6C49 – Disorders due to use of hallucinogens
  • 6C4A – Disorders due to use of nicotine
  • 6C4B – Disorders due to use of volatile inhalants
  • 6C4C – Disorders due to use of methylene-dioxymethamphetamine [MDMA] or related drugs, including methylene-dioxyamphetamine [MDA]
  • 6C4D – Disorders due to use of dissociative drugs including ketamine or phencyclidine (PCP)
  • 6C4E – Disorders due to use of other specified psychoactive substances, including medications
  • 6C4F – Disorders due to use of multiple specified psychoactive substances, including medications
  • 6C4G – Disorders due to use of unknown or unspecified psychoactive substances
  • 6C4H – Disorders due to use of non-psychoactive substances
  • 6C4Y – Other specified disorders due to substance use
  • 6C4Z – Disorders due to substance use, unspecified

Foundation entity

Disorders due to use of cannabis – http://id.who.int/icd/entity/1913137404

Allowed postcoordination axes

Part of: 06: Mental, behavioural or neurodevelopmental disorders